Hello! I'm your financial news analysis assistant. This article about "China's most impressive pharmaceutical couple" tells a very significant and dramatic story: it represents the complete transformation of China's pharmaceutical industry from an era of imitation to one of innovation and international expansion.
To help you easily understand the complex business logic behind this, I'll first summarize the main points in one sentence and then break it down into five aspects, explaining them in plain language.
📌 Core Summary
Hengrui Medicine (led by Sun Piaoyang) and Hansoh Pharmaceutical (led by Zhong Huijuan), two companies that originated in Lianyungang, Jiangsu, now have a combined market value of over 450 billion RMB and both rank among the top pharmaceutical companies in China. Although they both started with generic drugs and experienced the challenges of government-led price cuts, their transformation paths are quite different: Hengrui has adopted a "large-scale, comprehensive" approach, acting like a massive research and development (R&D) factory, aiming to dominate the global market on its own; Hansoh, on the other hand, has chosen a "precision, high-quality" strategy, focusing on producing premium drugs for global giants like GSK and Merck to generate profits.
The core message of this article is that Chinese pharmaceutical companies are no longer just manufacturing drugs for foreign companies or selling cheap products; they are beginning to take control of the innovation process and are even being sought after by global leaders.
---
🔍 In-Depth Analysis: Five Aspects to Understand the Business Strategies of This "Pharmaceutical Couple"
1. Common Origins: Why Did Lianyungang Produce Two Giants?
Many people think that Suzhou and Shanghai are the centers of the pharmaceutical industry, but Hengrui and Hansoh both come from Lianyungang. This is due to a historical factor: the "industrialization benefits" of the region.
- Early Stage (1990s - Early 2000s): At that time, what Chinese pharmaceutical companies lacked was not the ability to invent new drugs, but the capability to produce, manufacture, and stabilize them at low costs. Lianyungang happened to have the right conditions, with a complete industrial chain in place (including talent, equipment, and related industries).
- Initial Accumulation: When Sun Piaoyang took over Hengrui, it was a small company with an annual profit of only 80,000 RMB. They built a strong production and sales network by focusing on generic drugs, especially anti-cancer drugs.
- Critical Turning Point: With the cash flow from drug sales, they had the funds to invest in R&D. The environment in Lianyungang allowed these two companies to accumulate the necessary capital to enter the era of innovative drugs.
> 💡 In Simple Terms: It's like running a restaurant; you first need to cook efficiently and reliably (producing generic drugs), and then you can afford to develop new recipes (innovative drugs). Lianyungang provided the foundation for these companies to develop their skills.
2. Different Paths to Innovation: Why Do They Earn Money Differently?
Both companies have shifted to innovative drugs, but their approaches are distinct. Looking at the data from the first half of 2026, the differences are clear:
- Hengrui (the "Super R&D Factory"):
- Characteristics: Large team of R&D personnel (over 5,600), multiple pipeline projects (over 100 in development), and a wide range of technologies (ADC, bispecific antibodies, small nucleic acids, etc.).
- Strategy: A broad approach, hoping that one of the many projects will succeed.
- Financial Performance: High revenue, but traditional generic drugs still account for a large portion, so overall growth is slower (revenue slightly down), although the proportion of innovative drugs has exceeded 60%.
- Logic: Leveraging scale to reduce risks and maintain a steady output of innovative products.
- Hansoh (the "Premium Asset Hunter"):
- Characteristics: Smaller R&D team (over 2,500), but more focused.
- Strategy: Concentrating on developing drugs with high potential for global success, such as ADC and GLP-1 weight loss drugs.
- Financial Performance: Lower revenue than Hengrui (about 54%), but higher profits (nearly 95%) due to a higher proportion of innovative drugs (over 85%).
- Logic: Producing the best drugs and selling them to global giants for upfront payments and milestone payments, avoiding the need to build sales networks globally.
> 💡 In Simple Terms: Hengrui is like a large central kitchen with many chefs, constantly creating new dishes; Hansoh is like a Michelin-starred chef, specializing in a few signature dishes and selling the recipes and finished products to global chains.
3. Hengrui's Strength: From "Selling Drugs" to "Selling R&D Capability"
With a market value of nearly 280 billion RMB, Hengrui's key achievement is that global giants are now paying for its R&D system, not just for individual drugs.
- Iconic Event: In May 2026, Hengrui signed a major deal with Bristol-Myers Squibb (BMS), a top global pharmaceutical company.
- Previously: Hengrui sold a drug to BMS, and BMS paid.
- Now: BMS not only buys Hengrui's drugs but also collaborates on the discovery of future drugs, with BMS contributing to early development. The potential total payment from BMS is as high as 15.2 billion US dollars.
- What Does This Mean? BMS recognizes Hengrui's R&D capabilities. Hengrui is evolving from a Chinese pharmaceutical company to a global R&D platform, selling not just products but also its ability to develop new drugs.
- Global Expansion: Hengrui is building its own global team and has entered more than 50 countries, aiming to control the market independently, rather than relying on licensing agreements.
> 💡 In Simple Terms: Hengrui used to be a seller; now it's a technology partner, with BMS providing funding and expertise for joint R&D. This shows that Hengrui's technology is so advanced that it attracts investment from global leaders.
4. Hansoh's Smart Strategy: Leveraging "Light Assets" for "Heavy Value"
With a market value of about 200 billion RMB, Hansoh's strategy is to offload the heavy burden of global commercialization to other companies.
- Core Approach: License-out (licensing its drugs internationally).
- Benefits: Quick capital return—e.g., selling an ADC drug to GSK for an upfront payment, with additional revenue based on sales. This money can be used for the next drug's development.
- Advantages: Avoiding the cost of building sales teams in the US and Europe. Hansoh leverages the existing networks of GSK and Merck.
- Recent Progress:
- ADC Drugs: HS-20093 showed excellent results, reducing mortality risk by 54%, significantly increasing the value of the license agreement with GSK.
- Weight Loss Drugs: Hansoh sold HS-10535 to Merck and HS-20094 to Regeneron.
- New Approach: Hansoh is also investing in partners (e.g., Avere), holding shares and sharing in their growth.
> 💡 In Simple Terms: Hansoh is like a talented designer who creates popular products. Instead of opening its own stores globally, it licenses its designs to giants like Zara and Uniqlo, which handle production, distribution, and sales, allowing Hansoh to earn higher profits with less investment.
5. The Ultimate Question: When Will China Produce Its Own Global Big Pharma?
The article raises an important question: Chinese pharmaceutical companies are strong, but they are still one step away from becoming true global giants.
- Current Situation: Chinese companies like Hengrui and Hansoh can produce top-tier innovative drugs and are being acquired by global giants for high prices. This is the "asset-selling" phase.
- Gaps: True global Big Pharmas (like Pfizer and Novartis) can not only develop drugs but also conduct clinical trials, register, price, and sell them in over 100 countries.
- Two Paths:
- Hengrui's Path: Working to develop the necessary capabilities to control the global market and become a true Big Pharma. This path is challenging but offers greater potential.
- Hansoh's Path: Continuing to be an asset provider, maximizing value through effective business development. This path is more stable but may require reliance on partners.
- Industry Trend: The global pharmaceutical industry is reorganizing, with China focusing on discovery and early clinical trials (due to efficiency and cost advantages), and global giants handling later stages and commercialization.
> 💡 In Simple Terms: Chinese companies are currently suppliers, earning substantial profits. To become global brands, they need to learn to operate and market their products globally. Hengrui is learning how to do this, while Hansoh is focusing on optimizing its supply agreements.
---
📝 Conclusion
The story of this "pharmaceutical couple" reflects the transformation of China's pharmaceutical industry over the past three decades:
1. Past: Relying on generic drugs, focusing on manufacturing and distribution.
2. Present: Innovating with drugs, focusing on R&D and global collaboration.
3. Future: Hengrui and Hansoh represent two possible paths: becoming comprehensive global giants or efficient asset providers.
Regardless of the path chosen, this indicates that China's pharmaceutical industry has moved from a follower to a leader. For consumers, this means more, cheaper, and more effective domestic innovative drugs; for investors, these two companies are the most promising players in China's pharmaceutical innovation.